WAP-8294A₂, a novel anti-MRSA antibiotic produced by Lysobacter sp.

Azusa Kato, Seigo Nakaya, Yoshitami Ohashi, and Haruhisa Hirata
Wakamoto pharmaceutical Co., Ltd., Ohimachi, Ashigarakami-gun, Kanagawa 258, Japan

Kiyonaga fujii and ken-ichi Harada
Faculty of Pharmacy, Meijo University, Tempaku, Nagoya 468, Japan

Infectious diseases due to antibiotic-resistant bacteria pose a threat to public health around the world. Especially, nosocomial infections caused by methicillin-resistant Staphylococcus aureus (MRSA) in hospitals have become a serious clinical problem. Glycopeptide antibiotics, vasomycin and teicoplanin, are the drugs of choice for the treatment of MRSA infections. However, isolation of the glycopeptide-resistant S. aureus and in vitro transfer of the vacomycin-resistant genes from Enterococcus faecalis to S. aureus have been recently reported. Therefore, an antibacterial agent which differs from vancomycin in mode of action is clinically desirable. In the course of our screening for antibiotics, we found that a novel antibiotic, WAP-8294A₂ produced by a Gram-negative bacterium Lysobacter sp. showed higher in vivo activity against MRSA than vancomycin. (*)

Structure of WAP-8294A₂

(*) Kato, A.; Nakaya, S.; Ohashi, Y.; Hirata, H.; J. Am. Chem. Soc. 1997, 119, 6680-6681

Download
Paper1_JACS.pdf
(WAP-8294A2, A novel Anti-MRSA Antibiotic Produced by Lysobactor sp.)

Paper2_JARA.pdf
(A New Antibiotic Complex, WAP-8294A)

Nippon Medical Research, Inc. Address: Kita Aoyama 1-5-12/5F, Minato-ku,Tokyo 107-0061, Japan Phone: 813-5414-2614 Facsimile: 813-5414-2768